Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Renal Transplantation.
Phase of Trial: Phase IV
Latest Information Update: 13 Feb 2017
At a glance
- Drugs Paricalcitol (Primary) ; Calcifediol
- Indications Secondary hyperparathyroidism
- Focus Therapeutic Use
- Acronyms PARIDOINAL2013
- 10 Jun 2017 Biomarkers information updated
- 17 Oct 2015 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.
- 25 Sep 2015 Planned end date changed from 1 Sep 2015 to 1 Dec 2015, as reported by ClinicalTrials.gov.